单次注射后抗流行性猫杯状病毒感染的疫苗效力:Leucofeligen™ FeLV/RCP与Purevax™ RCPFeLV疫苗的比较
本研究评估两种多价商业疫苗在单次注射后对猫杯状病毒(FCV)组分的效力。接种组猫分别接受一剂Leucofeligen™ FeLV/RCP或Purevax™ RCPFeLV皮下注射,对照组不接种。注射3周后所有猫接种异源杯状病毒野毒株,评估杯状病毒病临床症状和病毒排毒。结果显示Leucofeligen™ FeLV/RCP在首剂初免后3周即可减少临床症状和病毒排泄,保护小猫抵抗FCV感染,而Purevax™ RCPFeLV在相似实验条件下未能提供同等水平保护。
要点
- Leucofeligen™ FeLV/RCP单次注射后3周可减少FCV临床症状和病毒排泄。
- Purevax™ RCPFeLV在相似实验条件下未提供同等水平保护。
- 所有猫在疫苗注射3周后接种异源杯状病毒野毒株。
核心结论
- Leucofeligen™ FeLV/RCP单次注射后3周可保护小猫抵抗FCV感染,减少临床症状和病毒排泄;Purevax™ RCPFeLV在相似实验条件下未能提供同等水平保护。
研究设计与样本
- 猫被分配至接种组,分别接受一剂Leucofeligen™ FeLV/RCP(Virbac,法国)或Purevax™ RCPFeLV(Boehringer Ingelheim,德国)皮下注射;对照组不接种任何疫苗。
- 疫苗注射3周后,所有猫接种异源杯状病毒野毒株,评估杯状病毒病临床症状和病毒排毒。
主要发现
- Leucofeligen™ FeLV/RCP在首剂初免后3周可减少临床症状和病毒排泄,保护小猫抵抗FCV感染。
- Purevax™ RCPFeLV在相似实验条件下未能提供同等水平保护。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Feline calicivirus (FCV) is a worldwide pathogen that affects the general health status of cats. The aim of this study was to assess the efficacy of the FCV component of two multivalent commercial vaccines after one injection. The cats assigned to the vaccinated groups received one subcutaneous injection of either the Leucofeligen™ FeLV/RCP (Virbac, France) vaccine or the Purevax™ RCPFeLV (Boehringer Ingelheim, Germany) vaccine. In the control group, the cats did not receive any vaccine. Three weeks after the vaccine injection, all the cats were inoculated with a heterologous calicivirus strain, isolated in the field. The clinical signs of calicivirosis and the viral shedding were assessed. The results demonstrated that Leucofeligen™ FeLV/RCP could protect kittens against FCV infection by reducing clinical signs and viral excretion from 3 weeks after the first injection of primary vaccination, whereas Purevax™ RCPFeLV couldn't offer the same level of protection in similar experimental conditions.
引用
- Arcidiaco S, Schreiber P, Poincelot L, et al. Vaccines efficacy against infection with circulating feline calicivirus after one single injection: Comparison of Leucofeligen™ FeLV/RCP and Purevax™ RCPFeLV vaccines. Vaccine. 2024. PMID: 39332239. doi:10.1016/j.vaccine.2024.126393
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。